
Accelerating Growth Through Clarity


About the Firm
Allied Pacific Partners is a strategic advisory firm that serves as an outsourced corporate development function for founders, management teams, and boards without one. We help clients think through the questions a well-resourced corporate development team would own internally: How should we finance our next stage of growth? Should we build, partner, or acquire? What does our capital structure need to look like to support the next two to three years?
Our approach is grounded in two decades of investment banking and capital markets experience — including transactions and strategic mandates exceeding $800 million across healthcare, life sciences, and technology. That background shapes how we think: the financial discipline, valuation frameworks, and pattern recognition of an institutional dealmaker, applied to the strategic and planning work companies need well before — or entirely apart from — any capital markets transaction.
Today, our work is analytical and advisory — financial modeling, valuation benchmarking, competitive and market assessment, and board-level strategic counsel — rather than transaction execution. We help clients reach clear, well-supported strategic decisions, and when a transaction or financing makes sense, we help prepare the company to pursue it credibly, working alongside the client's bankers, counsel, and other transaction professionals as needed.
While we are industry-agnostic, we've built particular depth in healthcare, life sciences, and technology.
Every engagement is senior-led. You work directly with someone who has been on both sides of the strategic table — as an advisor and as a principal — and who treats corporate development as an ongoing discipline, not a one-time deal.
Services

Corporate Development Strategy
We function as a fractional or outsourced corporate development team for companies that need this capability but aren't yet large enough to build it in-house. This includes ongoing evaluation of build-vs-buy decisions, competitive and market landscape analysis, partnership and joint-venture assessment, and maintaining a disciplined view of strategic options as the business evolves.
The goal is to bring the rigor of a well-run corp dev function — financial modeling, structured decision frameworks, and pattern recognition from prior transactions — to companies operating without one.

Capital Structure & Financing Strategy
Before any financing decision, we help management teams and boards work through the analysis: what capital is actually needed, what structure fits the business (equity, debt, or a blend), how much dilution or leverage is acceptable, and how the timing intersects with the company's broader strategic plan.
This is preparatory and advisory work — building the financial model, benchmarking terms against market comparables, and pressure-testing the narrative — done in advance of and independent of any capital-raising process itself.

Stategy & Transaction Readiness
For companies considering a future sale, acquisition, or major strategic transaction, we help management teams and boards get organized well before the process begins: cleaning up the financial story, identifying the value drivers and risks a counterparty will scrutinize, and building the internal case for the strategic path under consideration.
We also advise boards directly on strategic decisions that may never become a transaction—evaluating options, stress-testing assumptions, and serving as an experienced sounding board at the board level.

Principal


Selected Transactions
Halozyme Therapeutics

Halozyme Therapeutics
(NASDAQ: HALO)
Advised on strategic and financial matters related to its initial public offering and capital markets growth strategy.
Apthera

Apthera — Acquired by Galena BioPharma
Advised on strategic evaluation and preparation related to Apthera's acquisition by Galena BioPharma, a publicly traded biopharmaceutical company.
China TransInfo Technology

China TransInfo Technology
(SHE: 002373)
Advised on and structured strategic cross-border financing and a NASDAQ listing prior to relisting in China.

